NASDAQ
31.10.25 | 20:57
16,890 US-Dollar
-1,23 % -0,210
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025 | 2 | GlobeNewswire (USA) | ||
| 27.10. | BrainsWay Makes Two Minority Investments In U.S. Mental Health Providers | 1 | RTTNews | ||
| 27.10. | BrainsWay secures two more U.S. mental health provider investments | 1 | Investing.com | ||
| 27.10. | BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers | 142 | GlobeNewswire (Europe) | Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term shareholder value BURLINGTON, Mass. and JERUSALEM, Oct. 27, 2025 (GLOBE... ► Artikel lesen | |
| 27.10. | Brainsway Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 14.10. | Brainsway Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.09. | Brainsway Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 16.09. | BrainsWay rises as FDA clears accelerated Deep TMS protocol | 2 | Seeking Alpha | ||
| BRAINSWAY Aktie jetzt für 0€ handeln | |||||
| 16.09. | Brainsway stock surges after FDA clears accelerated depression treatment | 1 | Investing.com | ||
| 16.09. | FDA-Zulassung für beschleunigte Depressionstherapie beflügelt Brainsway-Aktie | 1 | Investing.com Deutsch | ||
| 16.09. | FDA clears accelerated protocol for BrainsWay Deep TMS in depression | 1 | MassDevice | ||
| 16.09. | BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD) | 183 | GlobeNewswire (Europe) | Clinical data shows that BrainsWay's new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response and remission The accelerated protocol is now... ► Artikel lesen | |
| 11.09. | Brainsway Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 25.08. | Brainsway stock maintains Buy rating at H.C. Wainwright after strategic investments | 1 | Investing.com | ||
| 21.08. | BrainsWay Falters on New Investment | - | Baystreet.ca | ||
| 21.08. | BrainsWay investiert in Neurolief vor Zulassung eines neuartigen Depressions-Therapiegeräts | - | Investing.com Deutsch | ||
| 21.08. | BrainsWay invests in Neurolief ahead of depression device launch | 1 | Investing.com | ||
| 21.08. | Neurolief Prepares for Launch of its ProlivRx System for Major Depressive Disorder with Strategic Investment from BrainsWay | 258 | PR Newswire | CORAL SPRINGS, Fla. and NETANYA, Israel, Aug. 21, 2025 /PRNewswire/ -- Neurolief, a pioneering brain stimulation company specializing in non-invasive neuromodulation therapies, today announced... ► Artikel lesen | |
| 21.08. | BrainsWay invests in neuromod developer Neurolief with option to buy | 3 | MassDevice | ||
| 21.08. | BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd. | 2 | GlobeNewswire (USA) |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 7,495 | +0,40 % | Teladoc stock rating reiterated at Hold by Stifel amid growth challenges | ||
| ALIGNMENT HEALTHCARE | 16,870 | -1,75 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 33,040 | +0,76 % | BrightSpring Health Services GAAP EPS of $0.17 misses by $0.15, revenue of $3.33B misses by $20M | ||
| SIEMENS HEALTHINEERS | 48,630 | +0,12 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 46,390 | -0,37 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| FRESENIUS | 49,720 | -0,60 % | DEUTSCHE BANK RESEARCH stuft Fresenius SE auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Fresenius von 52 auf 53 Euro angehoben und die Einstufung auf "Buy" belassen. Die anstehenden Quartalszahlen des Medizinkonzerns... ► Artikel lesen | |
| GENEDX | 137,17 | +4,20 % | GeneDx raises 2025 revenue guidance to $428M amid accelerating exome and genome test growth | ||
| GERRESHEIMER | 27,280 | -1,16 % | Gerresheimer: Weitere Details - millionenschwere Fehlbuchung | Am Wochenende hat der Spezialverpackungshersteller Gerresheimer per Ad-Hoc-Mitteilung dem Kapitalmarkt weitere Details zur laufenden Prüfung problematischer Buchungen im Konzernbericht für das Fiskaljahr... ► Artikel lesen | |
| BUTTERFLY NETWORK | 2,695 | +31,78 % | Butterfly Network reaffirms $91M-$95M 2025 revenue target while accelerating AI and chip innovation | ||
| PROCEPT BIOROBOTICS | 34,040 | -1,02 % | PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance | SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| UNITEDHEALTH | 297,30 | +1,05 % | Earnings Preview - Teil 1: Make or Break für den Markt: Die Zahlen von UnitedHealth, Microsoft & Alphabet! | © Foto: Richard Drew/AP/dpaDiese in den kommenden Tagen (KW44) anstehenden US-Quartalszahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell eingepreisten Kursreaktionen... ► Artikel lesen | |
| BETA BIONICS | 27,210 | +1,61 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| PROGYNY | 18,690 | +0,27 % | Progyny, Inc.: Progyny Expands Global Benefits to Include Pregnancy, Postpartum, and Menopause | Global employers can now empower their workforces with comprehensive women's health benefits, supported by localized expertiseNEW YORK, Oct. 22, 2025. (Nasdaq: PGNY), a global leader in women's health... ► Artikel lesen | |
| CLEARPOINT NEURO | 23,230 | -1,90 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles | SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 24,280 | -0,94 % | Privia Health Group, Inc. - 8-K, Current Report |
BRAINSWAY LTD ADR gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -1,23 % bei einem Aktienkurs von 16,890 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRAINSWAY LTD ADR finden Sie auf Wallstreet Online.